Financials

News Discussions Technicals Seasonals

6541 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. It products include filgrastim, trastuzumab, pegfilgrastim, bevacizumab, and pertuzumab injections. The company was founded by Yu Tien Chao on May 8, 2013 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

6541 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company